Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪293.40 M‬USD
−2.65USD
‪−135.35 M‬USD
‪31.66 M‬
Beta (1Y)
3.46

About Monte Rosa Therapeutics, Inc.

CEO
Markus Warmuth
Headquarters
Boston
Employees (FY)
133
Founded
2019
ISIN
US61225M1027
FIGI
BBG00X2VGZQ3
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GLUE is 5.85 USD — it has decreased by 1.18% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Monte Rosa Therapeutics, Inc. stocks are traded under the ticker GLUE.
Monte Rosa Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
GLUE stock is 8.78% volatile and has beta coefficient of 3.46. Check out the list of the most volatile stocks — is Monte Rosa Therapeutics, Inc. there?
One year price forecast for Monte Rosa Therapeutics, Inc. has a max estimate of 22.00 USD and a min estimate of 9.00 USD.
GLUE earnings for the last quarter are −0.70 USD per share, whereas the estimation was −0.72 USD resulting in a 3.28% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Monte Rosa Therapeutics, Inc. earnings.
Monte Rosa Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪3.53 M‬ USD.
Yes, you can track Monte Rosa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
GLUE stock has fallen by 17.84% compared to the previous week, the month change is a 14.72% fall, over the last year Monte Rosa Therapeutics, Inc. has showed a 9.02% decrease.
GLUE net income for the last quarter is ‪−33.25 M‬ USD, while the quarter before that showed ‪−34.88 M‬ USD of net income which accounts for 4.68% change. Track more Monte Rosa Therapeutics, Inc. financial stats to get the full picture.
Today Monte Rosa Therapeutics, Inc. has the market capitalization of ‪293.40 M‬, it has increased by 10.44% over the last week.
No, GLUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GLUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monte Rosa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
GLUE reached its all-time high on Sep 7, 2021 with the price of 45.56 USD, and its all-time low was 2.44 USD and was reached on Oct 25, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 21, 2024, the company has 133.00 employees. See our rating of the largest employees — is Monte Rosa Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Monte Rosa Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Monte Rosa Therapeutics, Inc. stock shows the sell signal. See more of Monte Rosa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Monte Rosa Therapeutics, Inc. future price: according to them, GLUE price has a max estimate of 22.00 USD and a min estimate of 9.00 USD. Read a more detailed Monte Rosa Therapeutics, Inc. forecast: see what analysts think of Monte Rosa Therapeutics, Inc. and suggest that you do with its stocks.